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Dear Editor: 
 
Several issues around rule-out strategies utilising low concentrations of high-
sensitivity cardiac troponin (hs-cTn) assays taken at presentation to the Emergency 
Department (ED) remain unexplored.  Firstly, large-scale analyses investigating cut-
off concentrations for hs-cTnI (Abbott Architect) < 99th percentile, have failed to 
investigate outcomes which incorporate the full spectrum of clinically relevant acute 
coronary syndromes, namely emergency revascularization (1,2).  Secondly, whether 
these strategies work with the hs-cTnT (Roche Elecsys) assay are under-explored.  
Finally, the impact of laboratory rounding (ie. rounding the reported value up or down 
to the next whole integer depending on the exact post-decimal point value e.g. 
4.5ng/L to 5ng/L) upon diagnostic performance at low cut-off concentrations, and 
how this effects the proportion of patients potentially eligible for early discharge, 
remains unknown. 
In this post-hoc analysis of a prospectively recruited cohort we aimed to establish the 
diagnostic performance of a single hs-cTnT result taken at ED presentation in 
patients with a non-ischemic ECG, using the LoD and additional cut-off 
concentrations <99th percentile, and also the impact of laboratory rounding. 
The methods and results of the primary analysis have been published previously, 
including reporting of diagnostic accuracy at the LoD for hs-cTnT at ED presentation 
(3).  Patients aged ≥18 years with chest pain suggestive of cardiac ischemia and a 
non-ischemic ECG, for whom the treating physician determined 6-hour troponin 
testing was required, were prospectively recruited at a single center. Specific to this 
analysis hs-cTnT results from the LoD (<5ng/L) up to the 99th percentile (14ng/L) 
were analyzed and were available to one decimal place.  Rounding occurred up or 
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down to the nearest integer at all cut-off concentrations between the LoD and 99th 
percentile.  Assay results were not affected by a previously reported calibration shift 
(4). The outcome was the presence of MACE (death due to ischemic heart disease, 
cardiac arrest, emergency revascularization, cardiogenic shock, ventricular 
arrhythmia, high-degree atrioventricular block and incident/prevalent acute 
myocardial infarction) occurring within 30 days.    
In total, 922 patients were included.  Of these, 546 (59.2%) were male, mean age 
was 58.0 years (SD=13.3) and 95 (10.3%) developed MACE within 30 days.  
Baseline characteristics have been previously reported (3). 
Troponin concentrations were <LoD (5ng/L) in 210 (22.8%) of 922 patients when 
laboratory rounding was applied and 262 (28.4%) with unrounded values. The 
rounded LoD cut-off gave a sensitivity of 97.9% (95%CI 92.0-99.6) for MACE 
(Figure); negative predictive value (NPV) 99.0% (96.4-99.8) and negative likelihood 
ratio (NLR) 0.084 (0.014-0.325) (2).  The performance of the unrounded LoD cut-off 
value was nearly identical: sensitivity 97.9% (92.0-99.6), NPV 99.2% (97.1-99.9) and 
NLR 0.067 (0.012-0.259). 
The sensitivity for MACE decreased with increasing cut-off concentration.  Rounded 
and unrounded cut-off values >LoD, up to and including 14ng/L all had sensitivities 
<97% for MACE (Figure).   
Laboratory rounding led to a decrease in the proportion of patients potentially 
suitable for early discharge across all cut-off concentrations.  This effect only 
reached significance at the LoD, where 5.6% fewer patients would have been eligible 
for early discharge with rounding; 22.8% (20.2-25.6) rounded vs. 28.4% (CI 25.6-
31.4) unrounded. 
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We demonstrate that hs-cTnT taken at ED presentation can, using a cut-off of 
<5ng/L (LoD), identify >20% of patients as potentially suitable for discharge.  At this 
cut-off, for the outcome of MACE, diagnostic performance may fall to levels below 
that which is clinically acceptable (5). However, it should be noted that the composite 
outcome of MACE includes revascularization which, although important, is a 
subjective outcome.  We also demonstrate that cut-off values >LoD may not have 
adequate diagnostic performance for clinical implementation.  Laboratory rounding 
may significantly reduce the proportion of patients potentially suitable for early 
discharge using the LoD cut-off. 
Importantly, we have not analyzed those patients presenting early after symptom 
onset.  The diagnostic performance of low cut-off concentrations has been shown to 
fall in this subgroup (1).  Futhermore, we selected patients without new onset ECG 
changes diagnostic of ischemia.  Therefore, the population selected for this analysis 
were likely to be at lower risk when compared to prior studies, and diagnostic 
performance may be overestimated as a result.   
Given the medicolegal implications for missed MACE, clinicians must carefully 
consider whether a LoD strategy is ready for clinical implementation.  In particular, 
were clinicians to make a discharge decision based on an undetectable troponin, full 
consideration should be given to time from symptom onset, further risk-stratification, 
and the need for advanced cardiac testing.   
Whether strategies that utilize low cut-off concentrations of hs-cTn can be 
successfully implemented into clinical practice remains unknown. Further studies are 
required to determine the clinical and cost effectiveness of such strategies. 
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Figure Legend 
Figure.  Sensitivity 30 day MACE for a range of rounded and unrounded high-
sensitivity troponin T concentrations at presentation.  
Error bars: 95% Confidence Intervals 
 
 
